PL2176664T3 - Ccr4 jako marker nowotworowy - Google Patents

Ccr4 jako marker nowotworowy

Info

Publication number: PL2176664T3
Authority: PL; Poland
Prior art keywords: ccr4; cancer marker; marker; cancer
Prior art date: 2007-09-18

Application number

PL08806315T

Other languages

English (en)

Inventor

Frances Balkwill

Violet Slettenaar

Julia Wilson

Yaohe Wang

Tiziana Schioppa

Original Assignee

Cancer Research Tech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-18

Filing date

2008-09-18

Publication date

2014-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38670078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2176664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-18 Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd

2014-04-30 Publication of PL2176664T3 publication Critical patent/PL2176664T3/pl

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Oncology (AREA)

PL08806315T 2007-09-18 2008-09-18 Ccr4 jako marker nowotworowy PL2176664T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0718167A GB0718167D0 (en)	2007-09-18	2007-09-18	Cancer marker and therapeutic target
EP08806315.1A EP2176664B1 (en)	2007-09-18	2008-09-18	Ccr4 as cancer marker
PCT/GB2008/003160 WO2009037454A2 (en)	2007-09-18	2008-09-18	Cancer marker and therapeutic target

Publications (1)

Publication Number	Publication Date
PL2176664T3 true PL2176664T3 (pl)	2014-04-30

Family

ID=38670078

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL08806315T PL2176664T3 (pl)	2007-09-18	2008-09-18	Ccr4 jako marker nowotworowy
PL12182790.1T PL2533047T3 (pl)	2007-09-18	2008-09-18	Ccr4 jako cel terapeutyczny dla nowotworu
PL12183760T PL2535716T3 (pl)	2007-09-18	2008-09-18	Marker nowotworowy i cel terapeutyczny

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL12182790.1T PL2533047T3 (pl)	2007-09-18	2008-09-18	Ccr4 jako cel terapeutyczny dla nowotworu
PL12183760T PL2535716T3 (pl)	2007-09-18	2008-09-18	Marker nowotworowy i cel terapeutyczny

Country Status (11)

Country	Link
US (2)	US9134293B2 (pl)
EP (3)	EP2533047B1 (pl)
JP (2)	JP5774309B2 (pl)
AU (1)	AU2008300413B2 (pl)
CA (1)	CA2699702C (pl)
DK (3)	DK2535716T3 (pl)
ES (3)	ES2588507T3 (pl)
GB (1)	GB0718167D0 (pl)
PL (3)	PL2176664T3 (pl)
RU (2)	RU2529797C2 (pl)
WO (1)	WO2009037454A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0623815Y2 (ja)	1988-10-06	1994-06-22	株式会社大金製作所	エア回転継手のシール装置
GB0718167D0 (en)	2007-09-18	2007-10-31	Cancer Rec Tech Ltd	Cancer marker and therapeutic target
WO2010037042A2 (en)	2008-09-26	2010-04-01	The General Hospital Corporation	Methods for detecting and treating cancer
US11029313B2 (en)	2008-09-26	2021-06-08	The General Hospital Corporation	Method of treating cervical neoplasia in patients infected with human papilloma virus
GB0909906D0 (en) *	2009-06-09	2009-07-22	Affitech As	Antibodies
WO2011157678A1 (en) *	2010-06-14	2011-12-22	Qiagen Gmbh	Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) *	2010-12-15	2011-01-26	Immatics Biotechnologies Gmbh	Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US10266599B2 (en)	2010-12-07	2019-04-23	Cancer Research Technology Limited	Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en)	2010-12-07	2011-01-19	Affitech Res As	Antibodies
EP2771488B1 (en)	2011-10-24	2018-03-28	SignalChem Lifesciences Corporation	Carbonic anhydrase ix-related markers and use thereof
BR112014013138B1 (pt)	2011-12-01	2022-06-28	Chemocentryx, Inc	Compostos de anilinas substituídas como antagonistas de ccr(4) e composição farmacêutica compreendendo os mesmos
GB2512857A (en) *	2013-04-09	2014-10-15	Cancer Res Technology	Cancer biomarker
EP3065774B1 (en) *	2013-11-06	2021-05-26	Janssen Biotech, Inc.	Anti-ccl17 antibodies
SI3148579T1 (sl)	2014-05-28	2021-07-30	Agenus Inc.	Proti GITR antitelesa in postopki z njihovo uporabo
WO2016050904A1 (en) *	2014-10-01	2016-04-07	Sphingotec Gmbh	Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
EP3283886B1 (en) *	2015-04-17	2020-01-15	Eisai Inc.	Methods for treating lung cancer
US12366508B2 (en)	2015-07-30	2025-07-22	Qiagen Gmbh	Method of preparing a frozen biological sample
CN108883173B (zh)	2015-12-02	2022-09-06	阿吉纳斯公司	抗体和其使用方法
CN110603056A (zh) *	2017-05-19	2019-12-20	日本全药工业株式会社	基于ccr4阻断的调节性t细胞浸润抑制方法及犬的肿瘤性疾病的治疗方法
KR102817790B1 (ko)	2018-08-29	2025-06-05	케모센트릭스, 인크.	C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
EP3885452A1 (en) *	2020-03-23	2021-09-29	Koninklijke Philips N.V.	Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5786158A (en) *	1992-04-30	1998-07-28	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) *	1992-10-09	1994-08-30	Glaxo Inc.	Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) *	1993-03-19	1996-01-03	The Johns Hopkins University	ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en)	1995-01-27	1995-03-15	Glaxo Group Ltd	Substances and their uses
US6498015B1 (en)	1995-06-07	2002-12-24	Icos Corporation	Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) *	1999-01-15	2002-12-03	Millennium Pharmaceuticals, Inc.	Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en)	1999-01-15	2001-06-12	The Board Of Trustees Of The Leland Stanford Junior University	Modulation of systemic memory T cell trafficking
ATE402192T1 (de)	2000-03-03	2008-08-15	Kyowa Hakko Kogyo Kk	Anti-ccr4 antikörper und fragmente davon
US20020132836A1 (en)	2000-10-11	2002-09-19	Chemocentryx Inc.	Compounds and methods for modulating CCR4 function
AU2002213467A8 (en)	2000-10-11	2009-07-30	Chemocentryx Inc	Modulation of ccr4 function
SI1326617T1 (sl)	2000-10-18	2007-02-28	Schering Ag	Uporaba 11 beta-(4-acetilfenil)-17 beta-hidroksi-17 alfa-(1,1,2,2,2-pentafluoroetil)estra-4,9-dien-3-ona za pripravo zdravila za zdravljenje raka dojk, raka jajcnikov, endometrijskega raka, mieloma in meningioma
CA2439279A1 (en) *	2001-02-28	2002-09-06	Protein Design Labs, Inc.	Chemokine receptors and disease
US7144903B2 (en)	2001-05-23	2006-12-05	Amgen Inc.	CCR4 antagonists
WO2003014153A2 (en)	2001-08-10	2003-02-20	Topigen Pharmaceutique Inc.	Cellular virus receptors and methods of use.
CA2458627C (en)	2001-08-31	2013-09-10	Kyowa Kirin Co., Ltd.	Human cdr-grafted antibody and antibody fragment thereof
AU2003252478A1 (en)	2002-07-10	2004-02-02	Ono Pharmaceutical Co., Ltd.	Ccr4 antagonist and medicinal use thereof
WO2004045526A2 (en)	2002-11-15	2004-06-03	Morehouse School Of Medicine	Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
JP2007524362A (ja) *	2003-02-14	2007-08-30	サイグレスディスカバリー，インコーポレイテッド	癌における治療ｇｐｃｒ標的
US7807389B2 (en) *	2003-03-14	2010-10-05	University Of Rochester	Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv)	2003-06-04	2003-06-04	Astrazeneca Ab	Novel compounds
SE0301653D0 (sv)	2003-06-05	2003-06-05	Astrazeneca Ab	Novel compounds
WO2005023771A1 (ja)	2003-09-05	2005-03-17	Ono Pharmaceutical Co., Ltd.	ケモカインレセプターアンタゴニストおよびその医薬用途
EP1688436A4 (en) *	2003-10-08	2009-12-02	Kyowa Hakko Kirin Co Ltd	ANTIBODY COMPOSITION THAT IS ABLE TO SPECIFY CCR4 SPECIFICALLY
JPWO2005053741A1 (ja)	2003-12-04	2007-06-28	協和醗酵工業株式会社	ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
WO2005082865A1 (ja)	2004-02-27	2005-09-09	Astellas Pharma Inc.	縮合二環性ピリミジン誘導体
JP2007217282A (ja)	2004-03-04	2007-08-30	Astellas Pharma Inc	置換ピリミジン誘導体
WO2005106471A2 (en) *	2004-04-30	2005-11-10	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja)	2004-06-21	2007-10-18	Astellas Pharma Inc	キナゾリン誘導体
RU2296328C1 (ru) *	2005-09-21	2007-03-27	Общество с ограниченной ответственностью "ГЕН"	Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) *	2005-10-19	2007-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK2135949T3 (da)	2006-02-14	2013-02-04	Noxxon Pharma Ag	MCP-1-bindende nukleinsyrer
GB0718167D0 (en)	2007-09-18	2007-10-31	Cancer Rec Tech Ltd	Cancer marker and therapeutic target

2007
- 2007-09-18 GB GB0718167A patent/GB0718167D0/en not_active Ceased
2008
- 2008-09-18 DK DK12183760.3T patent/DK2535716T3/en active
- 2008-09-18 CA CA2699702A patent/CA2699702C/en not_active Expired - Fee Related
- 2008-09-18 US US12/679,002 patent/US9134293B2/en not_active Expired - Fee Related
- 2008-09-18 PL PL08806315T patent/PL2176664T3/pl unknown
- 2008-09-18 EP EP12182790.1A patent/EP2533047B1/en not_active Not-in-force
- 2008-09-18 DK DK12182790.1T patent/DK2533047T3/en active
- 2008-09-18 EP EP08806315.1A patent/EP2176664B1/en not_active Not-in-force
- 2008-09-18 RU RU2010123921/15A patent/RU2529797C2/ru not_active IP Right Cessation
- 2008-09-18 PL PL12182790.1T patent/PL2533047T3/pl unknown
- 2008-09-18 AU AU2008300413A patent/AU2008300413B2/en not_active Ceased
- 2008-09-18 ES ES12182790.1T patent/ES2588507T3/es active Active
- 2008-09-18 DK DK08806315.1T patent/DK2176664T3/da active
- 2008-09-18 ES ES12183760.3T patent/ES2612690T3/es active Active
- 2008-09-18 WO PCT/GB2008/003160 patent/WO2009037454A2/en not_active Ceased
- 2008-09-18 ES ES08806315.1T patent/ES2443541T3/es active Active
- 2008-09-18 PL PL12183760T patent/PL2535716T3/pl unknown
- 2008-09-18 EP EP12183760.3A patent/EP2535716B1/en not_active Not-in-force
- 2008-09-18 JP JP2010525420A patent/JP5774309B2/ja not_active Expired - Fee Related
2014
- 2014-07-14 RU RU2014128513A patent/RU2014128513A/ru not_active Application Discontinuation
2015
- 2015-06-30 JP JP2015131752A patent/JP6234967B2/ja not_active Expired - Fee Related
- 2015-08-11 US US14/823,755 patent/US10261099B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US9134293B2 (en)	2015-09-15
EP2533047B1 (en)	2016-05-11
US10261099B2 (en)	2019-04-16
CA2699702A1 (en)	2009-03-26
PL2535716T3 (pl)	2017-06-30
RU2529797C2 (ru)	2014-09-27
EP2533047A1 (en)	2012-12-12
ES2588507T3 (es)	2016-11-03
JP2010539508A (ja)	2010-12-16
DK2176664T3 (da)	2014-01-20
US20100278844A1 (en)	2010-11-04
WO2009037454A2 (en)	2009-03-26
EP2535716A2 (en)	2012-12-19
GB0718167D0 (en)	2007-10-31
JP2015212703A (ja)	2015-11-26
AU2008300413A1 (en)	2009-03-26
DK2533047T3 (en)	2016-08-22
RU2010123921A (ru)	2011-12-20
EP2176664A2 (en)	2010-04-21
PL2533047T3 (pl)	2016-11-30
EP2535716A3 (en)	2013-03-13
JP5774309B2 (ja)	2015-09-09
EP2535716B1 (en)	2016-11-02
DK2535716T3 (en)	2017-02-13
RU2014128513A (ru)	2016-02-10
WO2009037454A3 (en)	2009-05-07
AU2008300413B2 (en)	2014-09-11
US20160223572A1 (en)	2016-08-04
EP2176664B1 (en)	2013-11-06
JP6234967B2 (ja)	2017-11-22
ES2612690T3 (es)	2017-05-18
CA2699702C (en)	2018-03-06
ES2443541T3 (es)	2014-02-19

Publication	Publication Date	Title
PL2176664T3 (pl)	2014-04-30	Ccr4 jako marker nowotworowy
CY2024031I2 (el)	2026-02-25	Παραγωγο 4-πυριμιδινοσουλφαμιδης
EP2115162A4 (en)	2010-02-17	Adrb2 cancer markers
EP2170350A4 (en)	2011-09-28	SUBSTITUTED IMIDAZOHETEROCYCLES
ATE542825T1 (de)	2012-02-15	Substituierte piperidino-dihydrothienopyrimidine
PT2115472E (pt)	2014-02-14	Biomarcadores de cancro
EP2226315A4 (en)	2012-01-25	2-aminoquinazoline DERIVATIVE
BRPI0813500A2 (pt)	2015-01-06	Compostos antivirais
BRPI0821086A2 (pt)	2014-10-07	Compostos inseticidas
DK2152885T3 (da)	2014-08-18	Polynukleotidmarkører
DK2132326T3 (da)	2012-12-17	Fremgangsmåder
BRPI0811264A2 (pt)	2014-11-04	Compostos
BRPI0809996A2 (pt)	2014-10-14	Compostos
BRPI0814424A2 (pt)	2015-01-06	Compostos heterociclila
CY2022026I2 (el)	2023-06-09	Συμπλοκα πρωτεϊνων-πολυμερων
BRPI0815181A2 (pt)	2015-03-31	Compostos
ATE546446T1 (de)	2012-03-15	5-aminocyclylmethyl-oxazolidin-2-eins-derivativ
EP2202090A4 (en)	2010-12-08	MECHANICAL PIN
CR9342S (es)	2008-09-02	Regadera
BRPI0818645A2 (pt)	2015-04-07	Lápis
BRPI0816705A2 (pt)	2015-03-17	Derivatido de 6-pirimidinil-pirimid-2-ona
BRPI0814613A2 (pt)	2015-01-27	Compostos
EP2157084A4 (en)	2011-07-13	5-phenyl-3-pyridazinone derivative
BRPI0820430A2 (pt)	2015-05-26	Composto
ATE516287T1 (de)	2011-07-15	Neuartige chromen-2-on-derivate